CT-041 is under clinical development by CARsgen Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CT-041’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-041 is under development for the treatment of esophagogastric junction cancer, relapsed or refractory gastric and pancreatic cancer, adenocarcinoma of the stomach, gastroesophageal junction, or pancreas cancer. It is administered through intravenous route as an injection. The drug candidate acts by targeting claudin 18 isoform 2. The drug candidate is developed based on chimeric antigen receptor (CAR) T cell technology. It was under development for colon cancer.
CARsgen Therapeutics overview
CARsgen Therapeutics (CARsgen) operates as a clinical-stage immune-oncology company focused on developing Chimeric Antigen Receptor T cell therapies for cancer. Its pipeline products include CAR-GPC3-T for the treatment of late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma; CAR-EGFR targeting Glioblastoma (GBM); CAR-CD19-T against lymphoma and B cell leukemia; CAR-Claudin18.2-T for gastric and pancreatic cancers; and CAR-BCMA-T against multiple myeloma. The company works in strategic partnerships with Shanghai Cancer Institute, Renji Hospital and Changhai Hospital. CARsgen is headquartered in Shanghai, China.
For a complete picture of CT-041’s drug-specific PTSR and LoA scores, buy the report here.